Geetha Pillai, MD
Internal Medicine · Leesburg, VANPI 1356335301
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,933 of the $5,666 with a category attached, or 87.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,124, more than ten times the $88 reported in 2019. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $26.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$695
- Stryker$640
- Pfizer$392
- Amgen$388
- AstraZeneca$291
- plus $2K from 28 others
What the payments were for
- Travel & lodging$64011%
- Food & beverage$4,93387%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $1,152 |
| AbbVie | 35 | $695 |
| Stryker | 1 | $640 |
| Pfizer | 15 | $392 |
| Amgen | 19 | $388 |
| AstraZeneca | 16 | $291 |
| Astellas Pharma US Inc | 10 | $286 |
| Lilly USA, LLC | 12 | $249 |
| Noah Medical Corporation | 4 | $242 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Abbott | 6 | $125 |
| Supernus Pharmaceuticals, Inc. | 6 | $119 |
| Exact Sciences | 6 | $118 |
| GSK | 6 | $108 |
| Medtronic | 3 | $95 |
| Daiichi Sankyo Inc. | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Merck | 2 | $46 |
| Boehringer Ingelheim | 2 | $43 |
| Dexcom, Inc. | 1 | $40 |
| Lundbeck LLC | 2 | $38 |
| Globus Medical | 1 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Recor Medical Inc | 1 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| Bayer | 1 | $26 |
| Genentech USA, Inc. | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $22 |
| Baxter Healthcare | 1 | $18 |
| Novartis | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION$640
- Wegovy$234
- GALAXY$178
- Ozempic$111
How this compares
$5,666 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 47 | $73,163 |
| EliquisApixaban | 59 | $58,388 |
| JardianceEmpagliflozin | 39 | $51,697 |
| OzempicSemaglutide | 29 | $49,589 |
| MounjaroTirzepatide | 33 | $38,582 |
| FarxigaDapagliflozin Propanediol | 32 | $35,620 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $18,939 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $18,893 |
| XareltoRivaroxaban | 17 | $17,468 |
| JanuviaSitagliptin Phosphate | 22 | $16,900 |
| MyrbetriqMirabegron | 18 | $15,338 |
| LinzessLinaclotide | 19 | $15,278 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $7,756 |
| GemtesaVibegron | 12 | $5,597 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $249 | $111,74580 claims |
| PfizerEliquis | $392 | $58,38859 claims |
| Boehringer IngelheimJardiance | $43 | $51,69739 claims |
| Novo NordiskOzempic | $1,152 | $49,58929 claims |
| AstraZenecaFarxiga | $291 | $35,62032 claims |
| GSKBreo Ellipta | $108 | $18,89345 claims |
| MerckJanuvia | $46 | $16,90022 claims |
| AbbVieLinzess, Synthroid | $695 | $16,67664 claims |
| Astellas Pharma US IncMyrbetriq | $286 | $15,33818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Leesburg
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.